<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2503">
  <stage>Registered</stage>
  <submitdate>9/09/2009</submitdate>
  <approvaldate>9/09/2009</approvaldate>
  <nctid>NCT00981799</nctid>
  <trial_identification>
    <studytitle>Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL</studytitle>
    <scientifictitle>A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>T2008-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed T-Cell Acute Lymphoblastic Leukemia</healthcondition>
    <healthcondition>Relapsed T-Cell Lymphoblastic Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nelarabine
Treatment: drugs - Etoposide
Treatment: drugs - Cyclophosphamide
Treatment: drugs - Methotrexate
Treatment: drugs - Filgrastim

Treatment: drugs: Nelarabine
Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

Treatment: drugs: Etoposide
100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5

Treatment: drugs: Cyclophosphamide
Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.

Treatment: drugs: Methotrexate
Give between day 29 and 36 or when ANC&gt;750 and PLTS&gt;75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.
Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but &lt;2 years of age 10 mg for patients age greater than or equal to 2, but &lt;3 years of age 12 mg for patients greater than or equal to 3, but &lt; 9 years of age 15 mg for patients greater than or equal to &gt;9 years of age

Treatment: drugs: Filgrastim
5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is &gt; 1000/mm3 for two consecutive days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the maximum tolerated doses and dose-limiting toxicities (DLTs) of nelarabine, etoposide and cyclophosphamide when given in combination to children with T-ALL and bone marrow relapse or T-LL.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the complete remission rate after 1 and 2 courses of this therapy in children with T-ALL and bone marrow relapse or T-LL.</outcome>
      <timepoint>1-3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the percent of children with T-ALL and 1st BM relapse that have a complete response after therapy on this study and proceed to stem cell transplantation in complete response within 20 weeks of beginning this regimen.</outcome>
      <timepoint>5 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine minimal residual disease (MRD) levels at the end of each course of treatment.</outcome>
      <timepoint>60 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the vitamin B12 pathway and metabolites and the potential association of neurotoxicity following nelarabine therapy with alterations in this pathway.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine, in a preliminary manner, whether patients with relapsed T-ALL/LL have a distinct signaling signature that distinguishes malignant cells from normal thymocytes.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate, in a preliminary manner, whether phospho-flow cytometry can be used to predict clinical response to Nelarabine.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients to be enrolled in the dose-escalation portion of this study must have T-cell
             ALL or T-cell lymphoblastic lymphoma (LL) in first relapse or must have failed primary
             induction chemotherapy (ie, never attained a complete remission following an initial
             course of standard therapy for T-ALL or T-LL). Patients to be enrolled in the cohort
             expansion portion of this study (ie, those treated at the recommended phase 2 dose)
             must have T-cell ALL in first relapse or must have failed primary induction
             chemotherapy (ie, never attained a complete remission following an initial course of
             standard therapy for T-ALL). T-LL patients are not eligible for the cohort expansion
             phase.

          -  Patients with T-cell ALL must have greater than 25% blasts in the bone marrow with or
             without extramedullary disease.

          -  Patients with T-cell LL must have recurrent disease, documented by clinical or
             radiographic criteria, as well as histologic verification of the malignancy at
             original diagnosis. Patients with T-cell LL enrolled in the phase I dose-escalation
             study are not required to have measurable disease; however, patients enrolled in the
             phase II cohort expansion at the MTD must have measurable disease.

          -  Patients may have CNS 1 or CNS 2 disease but not CNS 3.

          -  ECOG 0-2 or Karnofsky = 50% for patients &gt; 16 years of age; Lansky = 50% for patients
             =16 years of age.

          -  Patients may be enrolled on study regardless of the timing of prior Intrathecal
             therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF 7
             DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY.

          -  At least 6 weeks must have elapsed since administration of nitrosureas.

          -  At least 12 weeks must have elapsed since administration of craniospinal or hemipelvic
             radiation.

          -  Female patients of childbearing potential must have a negative urine or serum
             pregnancy test confirmed within 2 weeks prior to enrollment.

          -  Female patients with infants must agree not to breastfeed their infants while on this
             study.

          -  Male and female patients of child-bearing potential must agree to use an effective
             method of contraception approved by the investigator during the study and for a
             minimum of 6 months after study treatment.

          -  Adequate renal function defined as serum creatinine = 1.5x upper limit of normal (ULN)
             for age. If the serum creatinine is above these values, the calculated creatinine
             clearance or radioisotope GFR must be = 70 mL/min/1.73m2.

          -  Total bilirubin = 1.5x ULN for age. If the total bilirubin is elevated, patient will
             still be eligible if the conjugated (direct) serum bilirubin = ULN for age.

          -  ALT = 5x ULN of normal for age.

          -  Adequate cardiac function defined as shortening fraction of = 27% by echocardiogram or
             ejection fraction = 45% by gated radionuclide study.

          -  No evidence of dyspnea at rest

          -  No exercise intolerance

          -  A pulse oximetry = 94% at sea level (= 90% at altitude = 5000 feet) if there is
             clinical indication for determination.

          -  Patients and/or their parents or legal guardians must be capable of understanding the
             investigational nature, potential risks and benefits of the study. All patients and/or
             their parents or legal guardians must sign a written informed consent.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with Down syndrome are excluded.

          -  Patients with pre-existing Grade 2 (or greater) peripheral motor or sensory
             neurotoxicity per the CTCAE 3.0 as determined by the treating physician or a
             neurologist.

          -  Patients with a history of prior veno-occlusive disease (VOD) or findings consistent
             with a diagnosis of VOD, defined as: conjugated serum bilirubin &gt;1.4 mg/dL AND
             unexplained weight gain greater than 10% of baseline weight or ascites AND
             hepatomegaly or right upper quadrant pain without another explanation, OR reversal of
             portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy.

          -  Previous hematopoetic stem cell transplantation.

          -  Patients with a prior seizure disorder requiring anti-convulsant therapy are not
             eligible to receive nelarabine. For the purposes of this study, this includes any
             patient that has received anticonvulsant therapy to prevent/treat seizures in the
             prior two years.

          -  Positive blood culture within 48 hours of study enrollment.

          -  Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection.

          -  Plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy
             during the study period.

          -  Any significant concurrent disease, illness, psychiatric disorder or social issue that
             would compromise patient safety or compliance, interfere with consent, study
             participation, follow up, or interpretation of study results.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Royal Children's Hospital - Brisbane</hospital>
    <hospital>Royal Children's Hospital, Melbourne - Melbourne</hospital>
    <hospital>Sydney Children's Hospital - Sydney</hospital>
    <hospital>Children's Hospital at Westmead - Westmead, NSW</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead, NSW</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Therapeutic Advances in Childhood Leukemia Consortium</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>GlaxoSmithKline</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novartis</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Nelarabine has shown significant activity in patients with T-cell malignancies. This study
      will determine the safety and maximum tolerated dose of the combination of nelarabine,
      cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first
      relapse of T-LL.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00981799</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jim Whitlock, MD</name>
      <address>The Hospital for Sick Children</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>